Dupilumab for prurigo nodularis: Case series and review of the literature

Jesper Grønlund Holm,Tove Agner,Carsten Sand,Simon Francis Thomsen

DOI: https://doi.org/10.1111/dth.13222

2020-01-16

Dermatologic Therapy

Abstract:BackgroundDupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin‐4 and interleukin‐13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off‐label with dupilumab, and a review of the existing literature. MethodsAll patients had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of dupilumab treatment in prurigo nodularis. ResultsThe physician's assessment of the patients revealed a good or excellent response to dupilumab treatment. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well‐tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range 1–4) were identified by the literature search. Complete response was noted in all 11 patients. ConclusionDupilumab appears to be a safe and well‐tolerated treatment with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.This article is protected by copyright. All rights reserved.

dermatology